	US 11,851,493 B2
	Trispecific antagonists
Jackie Sheng, Thousand Oaks, CA (US); and Bo Liu, Thousand Oaks, CA (US)
Assigned to GENSUN BIOPHARMA, INC., Newbury Park, CA (US)
Filed by GENSUN BIOPHARMA, INC., Newbury Park, CA (US)
Filed on Aug. 17, 2020, as Appl. No. 16/995,414.
Application 16/995,414 is a continuation of application No. 16/845,924, filed on Apr. 10, 2020, granted, now 11,518,813.
Application 16/845,924 is a continuation of application No. 16/457,343, filed on Jun. 28, 2019, granted, now 10,647,773, issued on May 12, 2020.
Claims priority of provisional application 62/823,989, filed on Mar. 26, 2019.
Claims priority of provisional application 62/691,658, filed on Jun. 29, 2018.
Prior Publication US 2021/0009696 A1, Jan. 14, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61P 35/00 (2006.01); C07K 16/22 (2006.01); C07K 14/00 (2006.01); C07K 14/71 (2006.01); C07K 16/46 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2863 (2013.01) [A61P 35/00 (2018.01); C07K 14/00 (2013.01); C07K 14/71 (2013.01); C07K 16/22 (2013.01); C07K 16/2803 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 16/468 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/64 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2318/10 (2013.01); C07K 2319/30 (2013.01); C07K 2319/32 (2013.01)]

20 Claims

1. A bispecific antibody, comprising:

a protein scaffold comprising an Fc fragment, wherein the Fc fragment comprises a CH3 domain;

a first targeting domain comprising a VEGFR component, wherein the first targeting domain comprises the amino acid sequence of SEQ ID NO:185 or 207; and

a second targeting domain comprising a peptide inhibitor of angiopoietin/Tie-2 signaling pathway, wherein the second targeting domain comprises the amino acid sequence selected from the group consisting of SEQ ID NOS:182, 184, 194, 195 and 196, and wherein the second targeting domain is inserted within the CH3 domain of the Fc fragment.